[go: up one dir, main page]

FR2892722B1 - METHANONE-TYPE COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS, IN PARTICULAR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES - Google Patents

METHANONE-TYPE COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS, IN PARTICULAR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES

Info

Publication number
FR2892722B1
FR2892722B1 FR0511159A FR0511159A FR2892722B1 FR 2892722 B1 FR2892722 B1 FR 2892722B1 FR 0511159 A FR0511159 A FR 0511159A FR 0511159 A FR0511159 A FR 0511159A FR 2892722 B1 FR2892722 B1 FR 2892722B1
Authority
FR
France
Prior art keywords
methanone
treatment
pharmaceutical compositions
cardiovascular diseases
type compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0511159A
Other languages
French (fr)
Other versions
FR2892722A1 (en
Inventor
Gerard Marguerie
Eric Malaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clinigenetics SA
Original Assignee
Clinigenetics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clinigenetics SA filed Critical Clinigenetics SA
Priority to FR0511159A priority Critical patent/FR2892722B1/en
Priority to PCT/FR2006/002439 priority patent/WO2007051920A1/en
Publication of FR2892722A1 publication Critical patent/FR2892722A1/en
Application granted granted Critical
Publication of FR2892722B1 publication Critical patent/FR2892722B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0511159A 2005-11-02 2005-11-02 METHANONE-TYPE COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS, IN PARTICULAR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES Expired - Fee Related FR2892722B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR0511159A FR2892722B1 (en) 2005-11-02 2005-11-02 METHANONE-TYPE COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS, IN PARTICULAR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
PCT/FR2006/002439 WO2007051920A1 (en) 2005-11-02 2006-10-31 Methanone compounds and the use thereof in pharmaceutical compositions, in particular for treating cardiovascular diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0511159A FR2892722B1 (en) 2005-11-02 2005-11-02 METHANONE-TYPE COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS, IN PARTICULAR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES

Publications (2)

Publication Number Publication Date
FR2892722A1 FR2892722A1 (en) 2007-05-04
FR2892722B1 true FR2892722B1 (en) 2008-08-15

Family

ID=36448590

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0511159A Expired - Fee Related FR2892722B1 (en) 2005-11-02 2005-11-02 METHANONE-TYPE COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS, IN PARTICULAR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES

Country Status (2)

Country Link
FR (1) FR2892722B1 (en)
WO (1) WO2007051920A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314091B2 (en) 2007-08-20 2012-11-20 Msd Oss B.V. N-benzyl,N'-arylcarbonylpiperazine derivatives
TW200922582A (en) * 2007-08-20 2009-06-01 Organon Nv N-benzyl, N'-arylcarbonylpiperazine derivatives
TW201006816A (en) * 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3786578B2 (en) * 1997-11-18 2006-06-14 帝人ファーマ株式会社 Cyclic amine derivatives and their use as pharmaceuticals
BR9913654A (en) * 1998-08-28 2001-11-27 Scios Inc P-38alpha kinase inhibitors
SE9904652D0 (en) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
WO2001064676A2 (en) * 2000-02-28 2001-09-07 Scios, Inc. INHIBITORS OF p38-α KINASE

Also Published As

Publication number Publication date
FR2892722A1 (en) 2007-05-04
WO2007051920A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
EP1765379A4 (en) CO-CRISTAL PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF
IL222880A (en) Peptides and uses thereof in the treatment and diagnosis of diseases and pharmaceutical compositions comprising the same
IL185462A0 (en) New pharmaceutical compositions useful in the treatment of pain
CL2007001993A1 (en) COMPOUNDS DERIVED FROM HYDROXYLATED AND METOXYLATED PYRIMIDILCICLOPENTANOS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND IN THE TREATMENT OF AN INFLAMMATORY, HYPERPROLIFERANT, CARDIOVASCULAR, NEURODEGENERAT DISEASE
NO332405B1 (en) Compound of 5-substituted quinoline and isoquinoline derivatives, process for their preparation, their use in the preparation of pharmaceutical agents for the treatment of inflammatory disease and pharmaceutical composition comprising the compound.
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2007101224A3 (en) Inhibitors of the unfolded protein response and methods for their use
CL2008001304A1 (en) COMPOUNDS DERIVED FROM REPLACED INDOL, INHIBITORS OF THE 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP); PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF SUCH DISEASES AS COPD, CARDIOVASCULAR DISEASE AND INFLAMMATION.
EP1985302A4 (en) MEDICAMENT FOR THE TREATMENT OF TUMORS AND USE THEREOF
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
IL191310A (en) Factor xa variant which increases hemostasis, pharmaceutical composition comprising the same and use thereof in the manufacture of medicaments for treatment of hemostasis- related disorders
CL2007002376A1 (en) COMPOUNDS DERIVED FROM REPLACED PIRROL; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; AND USE IN BACTERIAL DISEASES.
CL2007003038A1 (en) COMPOUNDS DERIVED FROM 2-PHENYL-6-AMINOCARBONIL-PYRIMIDINE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF OCLUSIVE VASCULAR DISORDERS.
EP1879616A4 (en) SYNTHESIS OF SUPERANTIBODIES AND USE FOR THE DETECTION, PREVENTION AND TREATMENT OF DISEASE
FR2887450B1 (en) CONCENTRATED INGREDIENT FOR THE TREATMENT AND / OR MODIFICATION OF SURFACES, AND ITS USE IN COSMETIC COMPOSITIONS
FR2869540B1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING B-CARBOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER
IL209879A0 (en) Substituted pteridines ,pharmaceutical compositions containing them and their use in the manufacture of medicaments for treating inflammatory diseases
EP2217238A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEIN DISEASES
IL215840A (en) 2,5-disubstituted arylsulfonamide compounds, pharmaceutical compositions comprising same and use thereof in treating ccr3-related diseases
FR2882654B1 (en) USE OF DIOSMETIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF THROMBOTIC DISEASES
IL194880A (en) Aminothiazole derivatives, their use in the treatment of diseases and pharmaceutical compositions comprising them
IL199214A (en) Product comprising a combination of pemirolast and a statin, pharmaceutical compositions and kit comprising the same and their use in the treatment of inflammatory disorders
NO20070892L (en) Compositions of N-glycolylneuraminic acid and their use in the treatment of colds.
FR2905270B1 (en) USE OF C7 SUGARS IN THE PREVENTION AND TREATMENT OF MYCOSES
FR2906468B1 (en) USE OF COMPOUNDS OF THE AVERMECTIN FAMILY FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20090731